当前位置: 首页 >> 检索结果
47. Bedaquiline Activity against Leprosy.
作者: Abdoulaye Fomba.;Fadima C Haidara.;Mamoudou Kodio.;Catherine Arama.;Emmanuelle Cambau.;Aurélie Chauffour.;Nicolas Veziris.;Bettina E Broeckling.;Alaine K Warren.;Bertrand Cauchoix.;Alexandre Alcaïs.;Laurent Marsollier.;Henri Assé.;Mary Jackson.;Samba Ousmane Sow.;Ousmane Faye.;Vincent Jarlier.;Stewart T Cole.;Charlotte Avanzi.;Alexandra Aubry.;Roch C Johnson.
来源: N Engl J Med. 2025年392卷21期2174-2176页 54. A Trial of Trimethoprim-Sulfamethoxazole in Pregnancy to Improve Birth Outcomes.
作者: Bernard Chasekwa.;Fortunate Munhanzi.;Lenin Madhuyu.;Gabriel Mbewe.;Vincent Mabika.;Dzivaidzo Chidhanguro.;Tendai Kofi.;Jonthan Munengiwa.;Hilda Mapfumo.;Mercy Musapa.;Sipho Shumba.;Elizabeth Hungwe.;Mary Nhokwara.;Nester Bushe.;Rudo Kufa.;Phatisiwe Mazula.;Muchaneta Chikombingo.;Alice Tengende.;Admire Zanga.;Asaph Ziruma.;Tsitsi Bere.;Success Munyengwa.;Charity Mudimbu.;Zvikomborero Murwira.;Shepherd Mudzingwa.;Eddington Mpofu.;Batsirai Mutasa.;Virginia Sauramba.;Elisha Masakadze.;Thompson Runodamoto.;Courage Chiorera.;Alfred Mushininga.;Claire D Bourke.;Ruairi C Robertson.;Jeniffer Perussolo.;Nikos Donos.;Chandiwana Nyachowe.;Mary Muchekeza.;Jefrey Chikunya.;Melanie Smuk.;Kuda Mutasa.;Naume V Tavengwa.;Lisa L Langhaug.;Robert Ntozini.;Stephen P Munjanja.;Andrew J Prendergast.
来源: N Engl J Med. 2025年392卷21期2125-2134页
Maternal infections underlie several adverse birth outcomes. Whether trimethoprim-sulfamethoxazole prophylaxis during pregnancy will improve birth outcomes is unknown.
55. Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.
作者: Eleftherios P Mamounas.;Hanna Bandos.;Julia R White.;Thomas B Julian.;Atif J Khan.;Simona F Shaitelman.;Mylin A Torres.;Frank A Vicini.;Patricia A Ganz.;Susan A McCloskey.;Peter C Lucas.;Nilendu Gupta.;X Allen Li.;Beryl McCormick.;Benjamin Smith.;Rahul D Tendulkar.;Vivek S Kavadi.;Koji Matsumoto.;Samantha Andrews Seaward.;William J Irvin.;Jolinta Y Lin.;Robert W Mutter.;Thierry M Muanza.;Jannifer Stromberg.;Reshma Jagsi.;Anna C Weiss.;Walter J Curran.;Norman Wolmark.
来源: N Engl J Med. 2025年392卷21期2113-2124页
The benefit of regional nodal irradiation in the treatment of breast cancer is well established for patients with pathologically positive axillary nodes, but whether it is also beneficial for patients whose nodes become pathologically tumor free (ypN0) after neoadjuvant chemotherapy remains unclear.
56. Corynebacterium diphtheriae Outbreak in Migrant Populations in Europe.
作者: Andreas Hoefer.;Helena Seth-Smith.;Federica Palma.;Stefanie Schindler.;Luca Freschi.;Alexandra Dangel.;Anja Berger.;Joshua D'Aeth.;Rebecca Cordery.;Enrique Delgado-Rodriguez.;Eva Gruner.;Domenica Flury.;Vladimira Hinic.;Julian Kofler.;Reto Lienhard.;Rob Mariman.;Oliver Nolte.;Adrian Schibli.;Julie Toubiana.;Marianna Traugott.;Stephanie Jacquinet.;Alexander Indra.;Norman K Fry.;Daniel Palm.;Andreas Sing.;Sylvain Brisse.;Adrian Egli.; .
来源: N Engl J Med. 2025年392卷23期2334-2345页
A surge of cases of Corynebacterium diphtheriae infection was observed in reception centers for migrants in Europe beginning in the summer of 2022. Most of the cases were cutaneous, although some respiratory cases as well as one death were reported. A pan-European consortium was created to assess the clinical, epidemiologic, and microbiologic features of this outbreak.
57. Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.
作者: Aurore Perrot.;Jérôme Lambert.;Cyrille Hulin.;Andrea Pieragostini.;Lionel Karlin.;Bertrand Arnulf.;Philippe Rey.;Laurent Garderet.;Margaret Macro.;Martine Escoffre-Barbe.;Julie Gay.;Thomas Chalopin.;Romain Gounot.;Jean-Marc Schiano.;Mohamad Mohty.;Xavier Leleu.;Salomon Manier.;Clara Mariette.;Carine Chaleteix.;Thorsten Braun.;Bernard De Prijck.;Hervé Avet-Loiseau.;Jean-Yves Mary.;Jill Corre.;Philippe Moreau.;Cyrille Touzeau.; .
来源: N Engl J Med. 2025年
Measurable residual disease (MRD) is a major prognostic factor in newly diagnosed multiple myeloma. An assessment of an MRD-guided consolidation strategy in patients who are eligible for autologous stem-cell transplantation (ASCT) may be useful.
59. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
作者: Giannis Mountzios.;Longhua Sun.;Byoung Chul Cho.;Umut Demirci.;Sofia Baka.;Mahmut Gümüş.;Antonio Lugini.;Bo Zhu.;Yan Yu.;Ippokratis Korantzis.;Ji-Youn Han.;Tudor-Eliade Ciuleanu.;Myung-Ju Ahn.;Pedro Rocha.;Julien Mazières.;Sally C M Lau.;Martin Schuler.;Fiona Blackhall.;Tatsuya Yoshida.;Taofeek K Owonikoko.;Luis Paz-Ares.;Tony Jiang.;Ali Hamidi.;Diana Gauto.;Gonzalo Recondo.;Charles M Rudin.; .
来源: N Engl J Med. 2025年
Tarlatamab, a bispecific delta-like ligand 3-directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer. Whether tarlatamab is more effective than chemotherapy in the treatment of patients whose small-cell lung cancer has progressed during or after initial platinum-based chemotherapy is not known.
60. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.
作者: Mario Campone.;Michelino De Laurentiis.;Komal Jhaveri.;Xichun Hu.;Sylvain Ladoire.;Anne Patsouris.;Claudio Zamagni.;Jiuwei Cui.;Marina Cazzaniga.;Timucin Cil.;Katarzyna J Jerzak.;Christian Fuentes.;Tetsuhiro Yoshinami.;Alvaro Rodriguez-Lescure.;Ahmet Sezer.;Andrea Fontana.;Valentina Guarneri.;Andrea Molckovsky.;Marie-Ange Mouret-Reynier.;Umut Demirci.;Yongqiang Zhang.;Olga Valota.;Dongrui R Lu.;Marcella Martignoni.;Janaki Parameswaran.;Xin Zhi.;Erika P Hamilton.; .
来源: N Engl J Med. 2025年
Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader that directly harnesses the ubiquitin-proteasome system.
|